Journal article
Immune responses to novel adenovirus type 26 and modified vaccinia virus Ankara-vectored ebola vaccines at 1 year
- Abstract:
- The Ebola virus vaccine strategies evaluated by the WHO in response to the recent outbreak in West Africa included a heterologous prime/boost schedule of the adenovirus type 26 vector vaccine encoding Ebola virus glycoprotein (Ad26.ZEBOV) and the modified vaccinia virus Ankara vector vaccine, encoding glycoproteins from Ebola virus, Sudan virus, Marburg virus, and Tai Forest virus nucleoprotein (MVA-BN-Filo). This schedule has been shown to induce immune responses that persist for 8-months post priming immunization, with 100% of vaccine recipients retaining Ebola virus glycoprotein-specific antibodies.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 193.7KB, Terms of use)
-
- Publisher copy:
- 10.1001/jama.2016.20644
Authors
- Publisher:
- American Medical Association
- Journal:
- Journal of the American Medical Association More from this journal
- Volume:
- 317
- Issue:
- 10
- Pages:
- 1075-1077
- Publication date:
- 2017-03-01
- Acceptance date:
- 2016-12-16
- DOI:
- EISSN:
-
1538-3598
- ISSN:
-
0098-7484
- Pubs id:
-
pubs:681088
- UUID:
-
uuid:1d5aa326-9df7-4853-a910-55c247bfc6be
- Local pid:
-
pubs:681088
- Source identifiers:
-
681088
- Deposit date:
-
2017-02-21
Terms of use
- Copyright holder:
- American Medical Association
- Copyright date:
- 2017
- Notes:
- © 2017 American Medical Association. All Rights Reserved.
If you are the owner of this record, you can report an update to it here: Report update to this record